Matches in SemOpenAlex for { <https://semopenalex.org/work/W3158587435> ?p ?o ?g. }
- W3158587435 endingPage "2271" @default.
- W3158587435 startingPage "2264" @default.
- W3158587435 abstract "Since the US Food and Drug Administration (FDA) approvals of parenteral decitabine and azacitidine, DNA methyltransferase inhibitors, otherwise referred to as DNA hypomethylating agents (HMAs), have been a mainstay in the treatment of higher-risk myelodysplastic syndromes. The development of oral HMAs has been an area of active interest; however, oral bioavailability has been quite poor due to rapid metabolism by cytidine deaminase (CDA). This led to the development of the novel CDA inhibitor cedazuridine, which was combined with an oral formulation of decitabine. Preclinical work demonstrated a pharmacokinetic and pharmacodynamic profile approximate to parenteral decitabine, leading to early-phase clinical trials of oral cedazuridine-decitabine (C-DEC) in myelodysplastic syndromes and chronic myelomonocytic leukemia (CMML). A combination of oral decitabine 35 mg with oral cedazuridine 100 mg was established as the recommended phase 2 dose. Phase 2 data confirmed bioequivalence of C-DEC when compared with parenteral decitabine, and a larger phase 3 trial has demonstrated similar results, leading to the FDA approval of C-DEC for use in intermediate/high-risk myelodysplastic syndrome (MDS) and CMML. This review will focus upon the current role of HMA therapy in MDS/CMML, preclinical and clinical development of C-DEC, and potential roles of oral HMA therapy in myeloid malignancies moving forward." @default.
- W3158587435 created "2021-05-10" @default.
- W3158587435 creator A5003321703 @default.
- W3158587435 creator A5036697187 @default.
- W3158587435 creator A5038290613 @default.
- W3158587435 creator A5060015628 @default.
- W3158587435 date "2021-04-27" @default.
- W3158587435 modified "2023-10-05" @default.
- W3158587435 title "Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies" @default.
- W3158587435 cites W1600365609 @default.
- W3158587435 cites W187238933 @default.
- W3158587435 cites W1966474816 @default.
- W3158587435 cites W1971717153 @default.
- W3158587435 cites W1974079495 @default.
- W3158587435 cites W1974293265 @default.
- W3158587435 cites W2004172747 @default.
- W3158587435 cites W2023444151 @default.
- W3158587435 cites W2043244590 @default.
- W3158587435 cites W2078294866 @default.
- W3158587435 cites W2081279521 @default.
- W3158587435 cites W2086492419 @default.
- W3158587435 cites W2088612988 @default.
- W3158587435 cites W2089392942 @default.
- W3158587435 cites W2095342617 @default.
- W3158587435 cites W2106082819 @default.
- W3158587435 cites W2106084333 @default.
- W3158587435 cites W2106401558 @default.
- W3158587435 cites W2106584820 @default.
- W3158587435 cites W2109895173 @default.
- W3158587435 cites W2113099773 @default.
- W3158587435 cites W2118119661 @default.
- W3158587435 cites W2118771330 @default.
- W3158587435 cites W2122607246 @default.
- W3158587435 cites W2128919238 @default.
- W3158587435 cites W2148428508 @default.
- W3158587435 cites W2152333235 @default.
- W3158587435 cites W2169007954 @default.
- W3158587435 cites W2210620858 @default.
- W3158587435 cites W2265091238 @default.
- W3158587435 cites W2312226365 @default.
- W3158587435 cites W2326726820 @default.
- W3158587435 cites W2339658711 @default.
- W3158587435 cites W2521557372 @default.
- W3158587435 cites W2575545223 @default.
- W3158587435 cites W2596295815 @default.
- W3158587435 cites W2625726302 @default.
- W3158587435 cites W2751645476 @default.
- W3158587435 cites W2780737657 @default.
- W3158587435 cites W2808807711 @default.
- W3158587435 cites W2921042490 @default.
- W3158587435 cites W2923645205 @default.
- W3158587435 cites W2986575254 @default.
- W3158587435 cites W2988566662 @default.
- W3158587435 cites W3013239621 @default.
- W3158587435 cites W3015984203 @default.
- W3158587435 cites W3028372384 @default.
- W3158587435 cites W3047793391 @default.
- W3158587435 cites W3048827006 @default.
- W3158587435 cites W3096384900 @default.
- W3158587435 cites W3097664152 @default.
- W3158587435 cites W3114952208 @default.
- W3158587435 cites W4240220710 @default.
- W3158587435 cites W4252225072 @default.
- W3158587435 cites W606465697 @default.
- W3158587435 doi "https://doi.org/10.1182/bloodadvances.2020002929" @default.
- W3158587435 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8095139" @default.
- W3158587435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33904891" @default.
- W3158587435 hasPublicationYear "2021" @default.
- W3158587435 type Work @default.
- W3158587435 sameAs 3158587435 @default.
- W3158587435 citedByCount "16" @default.
- W3158587435 countsByYear W31585874352021 @default.
- W3158587435 countsByYear W31585874352022 @default.
- W3158587435 countsByYear W31585874352023 @default.
- W3158587435 crossrefType "journal-article" @default.
- W3158587435 hasAuthorship W3158587435A5003321703 @default.
- W3158587435 hasAuthorship W3158587435A5036697187 @default.
- W3158587435 hasAuthorship W3158587435A5038290613 @default.
- W3158587435 hasAuthorship W3158587435A5060015628 @default.
- W3158587435 hasBestOaLocation W31585874351 @default.
- W3158587435 hasConcept C104317684 @default.
- W3158587435 hasConcept C111113717 @default.
- W3158587435 hasConcept C112705442 @default.
- W3158587435 hasConcept C126322002 @default.
- W3158587435 hasConcept C143998085 @default.
- W3158587435 hasConcept C150194340 @default.
- W3158587435 hasConcept C185592680 @default.
- W3158587435 hasConcept C190727270 @default.
- W3158587435 hasConcept C2776012956 @default.
- W3158587435 hasConcept C2776239401 @default.
- W3158587435 hasConcept C2777928532 @default.
- W3158587435 hasConcept C2778729363 @default.
- W3158587435 hasConcept C2780007613 @default.
- W3158587435 hasConcept C2780235182 @default.
- W3158587435 hasConcept C2780817109 @default.
- W3158587435 hasConcept C2910157418 @default.
- W3158587435 hasConcept C535046627 @default.
- W3158587435 hasConcept C55493867 @default.